Diabetes and Neuroaxonal Damage in Parkinson's Disease

Patients with Parkinson's disease (PD) with coexistent type 2 diabetes (T2DM) can manifest with more severe motor and cognitive phenotypes. The precise reasons for this remain unclear though underlying pathophysiological differences are increasingly implicated. More severe neuroaxonal injury in PD patients with T2DM was recently proposed as a potential mechanism for this. We explored this in the tracking Parkinson's study and confirmed these findings. Cases with T2DM had higher serum neurofilament light levels and this remained significant after correction for age and vascular risk factor burden. Disentangling the underlying mechanism for more rapid axonal damage will be important in the development of disease modifying therapies for PD.

[1]  K. Blennow,et al.  Plasma neurofilament light chain as a potential biomarker in Charcot‐Marie‐Tooth disease , 2020, European journal of neurology.

[2]  R. Barker,et al.  Combining biomarkers for prognostic modelling of Parkinson’s disease , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.

[3]  T. Foltynie,et al.  Insulin resistance and Parkinson’s disease: A new target for disease modification? , 2016, Progress in Neurobiology.

[4]  P. Calabresi,et al.  Neurofilament light chain as a biomarker in neurological disorders , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[5]  Y. Ben-Shlomo,et al.  The Impact of Type 2 Diabetes in Parkinson's Disease , 2021, medRxiv.

[6]  C. Gerloff,et al.  Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK‐PD Study) , 2022, Movement disorders : official journal of the Movement Disorder Society.